US › Healthcare

Aktis Oncology, Inc. Common stock (AKTS)

US · Healthcare · Biotechnology

$22.84+2.74%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$3.2M
Revenue YoY
-64.3%
Net profit
$-18.3M
Profit YoY
-185.4%
EPS
$-0.38
EPS estimate
$-0.33
Net margin
-567.9%

EPS came in at -0.38 against a street estimate of -0.33 — a miss of 15.2%.

Key statistics

Market cap
$1.22B
Forward P/E
0.0
P/B
2.41
Book value
$9.16
EPS (TTM)
$-1.21
52-week high
$34.19
52-week low
$14.72
50-day MA
$23.89
200-day MA
$20.89

Analyst view

with an average price target of $34.38.

Shareholding

Insiders
14.14%
Institutions
74.44%

Largest institutional holders

FundStake
MPM Oncology Impact Management LP8.75%
EcoR1 Capital, LLC8.73%
Blue Owl Capital Holdings LP5.72%
Wellington Management Company LLP4.19%
T. Rowe Price Investment Management,Inc.3.84%
BlackRock Inc3.82%
RTW INVESTMENTS, LLC2.88%
T. Rowe Price Associates, Inc.2.83%

Recent filings & reports

DocumentDate
Quarterly report · Q1 20262026-05-11
Results announced · Q2 20262026-05-11
Board / officer change · Q2 20262026-04-16
Results announced · Q1 20262026-03-30
Annual report FY20252026-03-30
Charter / bylaws change · Q1 20262026-01-12

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Aktis Oncology, Inc. Common stock — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.